EVFM (Evofem Biosciences) Moat Score: 2/10 (As of Jun. 30, 2026)


What is Evofem Biosciences Moat Score?

Evofem Biosciences EVFM -3.86% Moat Score is 2 as of Jun. 30, 2026. The stock has 5 warning signs investors should review. Among 1,401 Biotechnology companies, Evofem Biosciences ranks better than 58.1% on this metric.

Evofem Biosciences has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Evofem Biosciences has No Moat: Evofem Biosciences operates in a competitive pharmaceutical industry with limited market share and brand recognition. It lacks significant intellectual property, cost advantages, and regulatory barriers to establish a durable competitive position.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Evofem Biosciences might have No Moat - Very weak/transient advantages.

Evofem Biosciences  (OTCPK:EVFM) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Evofem Biosciences Moat Score Related Terms

EVFM vs LYRA, CLSDQ, ATXI: Moat Score Comparison

For the Biotechnology subindustry, Evofem Biosciences's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Evofem Biosciences Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evofem Biosciences's Moat Score distribution charts can be found below:

* The bar in red indicates where Evofem Biosciences's Moat Score falls into.


Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Evofem Biosciences (EVFM) has a Moat Score of 2 as of Jun. 30, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Evofem Biosciences ranks #587 out of 1401 companies in the Biotechnology industry, placing it in the top 41.9%.
Is Evofem Biosciences' Moat Score too high?
Evofem Biosciences' current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. Evofem Biosciences' value of 2 is 0% at this industry median. Based on the distribution chart, Evofem Biosciences ranks #587 out of 1401 companies in the Biotechnology industry, which is above the industry midpoint.
How does Evofem Biosciences' Moat Score compare to LYRA and CLSDQ?
According to the Biotechnology industry distribution chart, Evofem Biosciences ranks #587 out of 1401 companies for Moat Score. This puts Evofem Biosciences in the upper half of its industry. The industry median Moat Score is 2.00. Evofem Biosciences' value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,401 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Evofem Biosciences's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evofem Biosciences's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evofem Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Evofem Biosciences (EVFM) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading 20.3% below its estimated fair value. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Evofem Biosciences (EVFM), the current Moat Score is 2 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Evofem Biosciences Business Description

Address 7770 Regents Road, Suite 113-618, San Diego, CA, USA, 92122
Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing products to address unmet needs in women's sexual and reproductive health. The company's product, Phexxi (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy.